

# Marc A Riedl

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8837246/marc-a-riedl-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92  
papers

3,410  
citations

28  
h-index

57  
g-index

98  
ext. papers

4,183  
ext. citations

7.1  
avg, IF

5.31  
L-index

#	Paper	IF	Citations
92	Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 69, 602-16	9.3	410
91	Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 532-41	59.2	387
90	Oral sulforaphane increases Phase II antioxidant enzymes in the human upper airway. <i>Clinical Immunology</i> , <b>2009</b> , 130, 244-51	9	176
89	Randomized placebo-controlled trial of the bradykinin B1 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2011</b> , 107, 529-37	3.2	158
88	Importance of oxidative stress in the pathogenesis and treatment of asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , <b>2008</b> , 8, 49-56	3.3	151
87	Adverse drug reactions: types and treatment options. <i>American Family Physician</i> , <b>2003</b> , 68, 1781-90	1.3	132
86	Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. <i>Allergy and Asthma Proceedings</i> , <b>2012</b> , 33 Suppl 1, S145-56	2.6	121
85	Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1131-1140	59.2	118
84	US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2013</b> , 1, 458-67	5.4	118
83	Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 320, 2108-2121	27.4	103
82	Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 717-728	59.2	99
81	When is prophylaxis for hereditary angioedema necessary?. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2009</b> , 102, 366-72	3.2	71
80	The International/Canadian Hereditary Angioedema Guideline. <i>Allergy, Asthma and Clinical Immunology</i> , <b>2019</b> , 15, 72	3.2	68
79	Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2014</b> , 112, 163-169.e7	3.2	59
78	Current state of hereditary angioedema management: a patient survey. <i>Allergy and Asthma Proceedings</i> , <b>2015</b> , 36, 213-7	2.6	58
77	US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 132-150.e3	5.4	52
76	Critical appraisal of androgen use in hereditary angioedema: a systematic review. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2015</b> , 114, 281-288.e7	3.2	51

75	Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2018</b> , 6, 1733-1741.e3	5.4	48
74	Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2013</b> , 110, 295-932	3.2	47
73	Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. <i>Lancet, The</i> , <b>2017</b> , 390, 1595-1602	4.0	45
72	Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 1793-1802.e2	5.4	42
71	Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2016</b> , 4, 963-71	5.4	40
70	Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency. <i>Pediatrics</i> , <b>2016</b> , 138,	7.4	35
69	The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. <i>World Allergy Organization Journal</i> , <b>2018</b> , 11, 5	5.2	34
68	Current medical management of hereditary angioedema: results from a large survey of US physicians. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2011</b> , 106, 316-322.e4	3.2	31
67	Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2015</b> , 3, 417-23	5.4	29
66	Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 148, 164-172.e9	11.5	29
65	International Consensus on the Use of Genetics in the Management of Hereditary Angioedema. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 901-911	5.4	28
64	Hereditary angioedema from the patient’s perspective: A follow-up patient survey. <i>Allergy and Asthma Proceedings</i> , <b>2018</b> , 39, 212-223	2.6	28
63	Hereditary angioedema with normal C1-INH (HAE type III). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2013</b> , 1, 427-32	5.4	26
62	Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2012</b> , 108, 49-53	3.2	26
61	Initial high-dose nasal allergen exposure prevents allergic sensitization to a neoantigen. <i>Journal of Immunology</i> , <b>2005</b> , 174, 7440-5	5.3	26
60	Comparison of chromogenic and ELISA functional C1 inhibitor tests in diagnosing hereditary angioedema. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2015</b> , 3, 200-5	5.4	25
59	Threshold-stimulated kallikrein activity distinguishes bradykinin- from histamine-mediated angioedema. <i>Clinical and Experimental Allergy</i> , <b>2018</b> , 48, 1429-1438	4.1	25
58	Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 73, 1871-1880	9.3	24

57	Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2015</b> , 3, 206-212.e4	5.4	23
56	An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension. <i>Clinical and Translational Allergy</i> , <b>2017</b> , 7, 36	5.2	23
55	Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United States. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2017</b> , 119, 59-64	3.2	23
54	Response time for ecallantide treatment of acute hereditary angioedema attacks. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2010</b> , 105, 430-436.e2	3.2	20
53	Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2019</b> , 56, 207-218	12.3	19
52	Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiency. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2018</b> , 121, 673-679	3.2	18
51	Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 75, 2879-2887	9.3	17
50	Managing the female patient with hereditary angioedema. <i>Womens Health</i> , <b>2016</b> , 12, 351-61	3	17
49	Creating a comprehensive treatment plan for hereditary angioedema. <i>Immunology and Allergy Clinics of North America</i> , <b>2013</b> , 33, 471-85	3.3	17
48	Emerging Therapies in Hereditary Angioedema. <i>Immunology and Allergy Clinics of North America</i> , <b>2017</b> , 37, 585-595	3.3	16
47	Current medical management of hereditary angioedema: follow-up survey of US physicians. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2015</b> , 3, 220-7	5.4	16
46	Recombinant human C1 esterase inhibitor in the management of hereditary angioedema. <i>Clinical Drug Investigation</i> , <b>2015</b> , 35, 407-17	3.2	15
45	Factors associated with negative histamine control for penicillin allergy skin testing in the inpatient setting. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2015</b> , 115, 33-8	3.2	15
44	Emergency Department Management of Hereditary Angioedema Attacks: Patient Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2017</b> , 5, 128-134.e4	5.4	14
43	Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies. <i>BioDrugs</i> , <b>2019</b> , 33, 33-43	7.9	12
42	HAE update: special considerations in the female patient with hereditary angioedema. <i>Allergy and Asthma Proceedings</i> , <b>2013</b> , 34, 13-8	2.6	11
41	Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 76, 1188-1198	9.3	11
40	Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1621	0.7	10

39	Definition, aims, and implementation of GA LEN/HAEi Angioedema Centers of Reference and Excellence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 75, 2115-2123	9.3	10
38	Utility of minor determinants for skin testing in inpatient penicillin allergy evaluation. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2017</b> , 119, 258-261	3.2	10
37	Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2017</b> , 118, 452-455	3.2	9
36	New therapeutics in C1INH deficiency: a review of recent studies and advances. <i>Current Allergy and Asthma Reports</i> , <b>2011</b> , 11, 300-8	5.6	9
35	Patient perspectives on the treatment burden of injectable medication for hereditary angioedema. <i>Allergy and Asthma Proceedings</i> , <b>2021</b> , 42, S4-S10	2.6	9
34	Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2017</b> , 5, 1091-1097	5.4	8
33	Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States. <i>Orphanet Journal of Rare Diseases</i> , <b>2018</b> , 13, 180	4.2	8
32	Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study. <i>Allergy, Asthma and Clinical Immunology</i> , <b>2019</b> , 15, 49	3.2	7
31	Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema. <i>Clinical and Experimental Allergy</i> , <b>2018</b> , 48, 1325-1332	4.1	7
30	Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2017</b> , 5, 442-447.e1	5.4	7
29	Recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks with upper airway involvement. <i>Allergy and Asthma Proceedings</i> , <b>2017</b> , 38, 462-466	2.6	7
28	Hereditary angioedema and shared decision making. <i>Allergy and Asthma Proceedings</i> , <b>2020</b> , 41, S55-S60	2.6	7
27	Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 2035-2038	5.4	6
26	Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial. <i>Allergy, Asthma and Clinical Immunology</i> , <b>2020</b> , 16, 8	3.2	6
25	The international WAO/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update.. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2022</b> ,	9.3	6
24	Current medical management of hereditary angioedema: Follow-up survey of US physicians. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2021</b> , 126, 264-272	3.2	6
23	Androgen use in hereditary angioedema: A critical appraisal and approaches to transitioning from androgens to other therapies. <i>Allergy and Asthma Proceedings</i> , <b>2021</b> , 42, 22-29	2.6	6
22	The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.. <i>World Allergy Organization Journal</i> , <b>2022</b> , 15, 100627	5.2	6

21	Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report. <i>Allergy, Asthma and Clinical Immunology</i> , <b>2021</b> , 17, 40	3.2	5
20	Caregivers' Role in managing hereditary angioedema and perceptions of treatment-related burden. <i>Allergy and Asthma Proceedings</i> , <b>2021</b> , 42, S11-S16	2.6	5
19	Physician and patient perspectives on the management of hereditary angioedema: a survey on treatment burden and needs. <i>Allergy and Asthma Proceedings</i> , <b>2021</b> , 42, S17-S25	2.6	5
18	Experience with Intravenous Plasma-Derived C1-Inhibitor in Pregnant Women with Hereditary Angioedema: A Systematic Literature Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 1875-1880.e3	5.4	4
17	Update on the acute treatment of hereditary angioedema. <i>Allergy and Asthma Proceedings</i> , <b>2011</b> , 32, 11-6	2.6	4
16	Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. <i>Orphanet Journal of Rare Diseases</i> , <b>2021</b> , 16, 86	4.2	4
15	COVID-19 and hereditary angioedema: Incidence, outcomes, and mechanistic implications. <i>Allergy and Asthma Proceedings</i> , <b>2021</b> , 42, 506-514	2.6	4
14	Nanofiltered C1 esterase inhibitor for treatment of laryngeal attacks in patients with hereditary angioedema. <i>American Journal of Rhinology and Allergy</i> , <b>2013</b> , 27, 517-21	2.4	3
13	Consensus on treatment goals in hereditary angioedema: A Global Delphi initiative. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 148, 1526-1532	11.5	3
12	Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2021</b> , 61, 84-97	12.3	3
11	Insights into the treatment burden of hereditary angioedema in the evolving treatment landscape. <i>Allergy and Asthma Proceedings</i> , <b>2021</b> , 42, S1-S3	2.6	3
10	Cases of acquired C1 inhibitor deficiency treated with rituximab. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2016</b> , 4, 987-8	5.4	3
9	Efficacy of recombinant human C1 esterase inhibitor across anatomic locations in acute hereditary angioedema attacks. <i>Allergy and Asthma Proceedings</i> , <b>2018</b> , 39, 359-364	2.6	3
8	Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> ,	9.3	3
7	Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2020</b> , 125, 334-340.e1	3.2	2
6	Association Between Self-Reported Dental Hygiene Practices and Dental Procedure-Related Recurrent Angioedema Attacks in HAE Subjects: A Multicenter Survey. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 3162-3169.e5	5.4	1
5	C1 esterase inhibitor concentrates and attenuated androgens - Authors' Reply. <i>Lancet, The</i> , <b>2018</b> , 391, 1356	4.0	1
4	Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study. <i>Clinical and Experimental Allergy</i> , <b>2021</b> , 51, 1391-1395	4.1	1

- 3 Inhibition of Prekallikrein for Hereditary Angioedema.. *New England Journal of Medicine*, **2022**, 386, 1026-1033 1
- 2 Reply: To PMID 24565612. *Journal of Allergy and Clinical Immunology: in Practice*, **2014**, 2, 239-40 5.4
- 1 Dose effects of respiratory neoantigen exposure on primary allergic sensitization. *Clinical Pharmacology and Therapeutics*, **2005**, 77, P3-P3 6.1